Academic Journal
Beyond Foxp3 and TSDR: a dual epigenetic lock framework for treg stability and plasticity.
| Τίτλος: | Beyond Foxp3 and TSDR: a dual epigenetic lock framework for treg stability and plasticity. |
|---|---|
| Συγγραφείς: | Wang F; Huzhou Central Blood Station, Huzhou, China., Yang H; Huzhou Central Blood Station, Huzhou, China., Xu Z; Huzhou College of Life and Health, Huzhou, China., Song J; Huzhou Central Blood Station, Huzhou, China., Wang Z; Zhejiang Chinese Medical University, Hangzhou, China., Wang L; Huzhou Central Blood Station, Huzhou, China. |
| Πηγή: | Frontiers in immunology [Front Immunol] 2026 Sep 22; Vol. 17, pp. 1952451. Date of Electronic Publication: 2026 Sep 22 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| Ιατρικοί όροι (MeSH): | T-Lymphocytes, Regulatory*/immunology , T-Lymphocytes, Regulatory*/metabolism , Forkhead Transcription Factors*/genetics , Forkhead Transcription Factors*/immunology , Cell Plasticity*/genetics , Cell Plasticity*/immunology , Epigenesis, Genetic*, Humans ; Animals ; Super Enhancers ; Immune Tolerance ; DNA Methylation |
| Περίληψη: | Regulatory T cells (Tregs) maintain immune homeostasis by balancing lineage stability with functional adaptability. Although Foxp3 is central to Treg identity, Foxp3 expression alone does not fully explain the long-term maintenance of suppressive function or the capacity of Tregs to adapt to diverse tissue environments. Similarly, Foxp3 TSDR demethylation provides a durable epigenetic imprint but does not account for the dynamic regulation of broader Treg functional programs. Here, we propose the Dual Epigenetic Lock framework as a conceptual and testable model in which two complementary epigenetic layers contribute to Treg state regulation. The first lock consists of stable TSDR demethylation, which preserves lineage-associated Foxp3 expression competence. The second lock is proposed to involve Treg-associated super-enhancer networks that may stabilize suppressive transcriptional programs, regulate environmental adaptation, and constrain inappropriate inflammatory activation. This framework suggests that Treg stability emerges from the integration of durable lineage memory and dynamic functional regulation rather than from a single molecular determinant. Disruption of this balance may contribute to impaired immune tolerance in autoimmune diseases, whereas excessive reinforcement of suppressive regulatory programs may support tumor immune evasion. However, the extent to which these two epigenetic layers are mechanistically coupled remains unresolved. Emerging approaches including single-cell multi-omics, spatial epigenomics, and targeted epigenome engineering provide opportunities to test whether the dual-lock architecture predicts Treg state transitions and therapeutic responsiveness. This framework also provides a conceptual basis for two complementary therapeutic strategies: reinforcing Treg stability for immune tolerance and selectively modulating tumor-associated Treg programs for cancer immunotherapy. (Copyright © 2026 Wang, Yang, Xu, Song, Wang and Wang.) |
| Competing Interests: | The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | Front Immunol. 2025 Sep 26;16:1667851. (PMID: 41080543) Front Immunol. 2017 Mar 31;8:220. (PMID: 28408905) Sci Transl Med. 2021 Apr 7;13(588):. (PMID: 33827976) Mol Ther. 2023 Oct 4;31(10):2872-2886. (PMID: 37481700) Mol Ther Methods Clin Dev. 2025 Aug 14;33(3):101561. (PMID: 40955314) Clin Cancer Res. 2026 Mar 16;32(6):1036-1045. (PMID: 41543348) Biomark Res. 2025 Jul 15;13(1):97. (PMID: 40660400) Cell Mol Immunol. 2021 Dec;18(12):2618-2631. (PMID: 34759371) Nat Immunol. 2009 Nov;10(11):1170-7. (PMID: 19767756) Mol Ther. 2024 Nov 6;32(11):4075-4094. (PMID: 39245938) Nat Commun. 2025 Dec 10;17(1):527. (PMID: 41372159) JCI Insight. 2024 Nov 22;9(22):. (PMID: 39388288) Front Immunol. 2025 Jul 24;16:1621396. (PMID: 40777039) Front Immunol. 2018 Nov 05;9:2540. (PMID: 30455694) Nat Commun. 2015 Feb 19;6:6353. (PMID: 25695215) Nat Biotechnol. 2026 Sep;44(9):1470-1481. (PMID: 41120666) Nat Commun. 2019 Dec 13;10(1):5697. (PMID: 31836704) J Exp Med. 2016 Mar 7;213(3):377-97. (PMID: 26903244) Front Immunol. 2021 Apr 01;12:626193. (PMID: 33868244) Nat Immunol. 2025 Aug;26(8):1315-1328. (PMID: 40670618) Cell. 2018 Nov 1;175(4):998-1013.e20. (PMID: 30388456) Nat Genet. 2001 Jan;27(1):20-1. (PMID: 11137993) Trends Immunol. 2025 Feb;46(2):153-165. (PMID: 39890548) Nat Commun. 2019 May 1;10(1):2011. (PMID: 31043609) Cancer Res. 2021 Apr 15;81(8):1965-1976. (PMID: 33589517) Proc Natl Acad Sci U S A. 2024 Sep 3;121(36):e2404916121. (PMID: 39207730) Cell Rep. 2017 May 9;19(6):1176-1188. (PMID: 28494867) Nat Biotechnol. 2020 Dec;38(12):1408-1414. (PMID: 32747759) J Clin Invest. 2014 Jul;124(7):2977-87. (PMID: 24892807) Kidney Int Rep. 2022 Apr 06;7(6):1258-1267. (PMID: 35694562) iScience. 2023 Jun 17;26(7):107170. (PMID: 37456851) Cold Spring Harb Perspect Med. 2013 Nov 01;3(11):. (PMID: 24186492) Immunity. 2021 Apr 13;54(4):702-720.e17. (PMID: 33789089) J Exp Med. 2024 Sep 2;221(9):. (PMID: 38935023) BMC Mol Cell Biol. 2025 Aug 28;26(1):26. (PMID: 40877782) Mol Immunol. 2020 Nov;127:1-11. (PMID: 32866740) Sci Immunol. 2025 Jun 20;10(108):eadu7341. (PMID: 40540587) Immunity. 2015 Aug 18;43(2):251-63. (PMID: 26275994) J Immunol Res. 2018 Jun 14;2018:6985031. (PMID: 30013992) Immunity. 2024 Aug 13;57(8):1975-1993.e10. (PMID: 39047731) Cell. 2016 Oct 6;167(2):419-432.e16. (PMID: 27693353) Immunity. 2024 May 14;57(5):1005-1018.e7. (PMID: 38697116) Immunity. 2024 Jul 9;57(7):1586-1602.e10. (PMID: 38897202) JCI Insight. 2025 Dec 11;11(3):. (PMID: 41379555) Nat Rev Immunol. 2009 Feb;9(2):83-9. (PMID: 19114986) Nat Methods. 2014 Aug;11(8):817-820. (PMID: 25042786) Annu Rev Med. 2026 Jan;77(1):239-251. (PMID: 41232570) Int J Mol Sci. 2025 Jul 29;26(15):. (PMID: 40806470) Inflammation. 2024 Dec;47(6):2159-2172. (PMID: 38700792) Mol Ther Methods Clin Dev. 2025 Sep 30;33(4):101600. (PMID: 41146876) Nat Commun. 2025 Aug 16;16(1):7644. (PMID: 40818959) Cancer Res. 2021 Jun 1;81(11):2983-2994. (PMID: 33757978) Int J Mol Sci. 2021 Jul 01;22(13):. (PMID: 34281195) J Exp Med. 2004 Nov 15;200(10):1231-41. (PMID: 15534368) Nat Immunol. 2023 May;24(5):841-854. (PMID: 36928412) Int Immunol. 2017 Aug 1;29(8):365-375. (PMID: 29048538) Nat Commun. 2025 Mar 27;16(1):2993. (PMID: 40148272) Cell Rep. 2021 Dec 14;37(11):110124. (PMID: 34910919) ACS Synth Biol. 2024 Feb 16;13(2):413-427. (PMID: 38298016) Immunity. 2020 Jul 14;53(1):143-157.e8. (PMID: 32640256) J Mol Med (Berl). 2023 Sep;101(9):1153-1166. (PMID: 37594540) Immunol Invest. 2018 Aug;47(6):632-642. (PMID: 29851536) Immunity. 2015 Feb 17;42(2):265-278. (PMID: 25680272) Signal Transduct Target Ther. 2025 Oct 14;10(1):345. (PMID: 41087343) Front Immunol. 2025 May 23;16:1604483. (PMID: 40486506) J Immunother Cancer. 2026 Mar 30;14(3):. (PMID: 41912269) Clin Exp Immunol. 2019 Jul;197(1):52-63. (PMID: 30913302) Immunity. 2012 Nov 16;37(5):785-99. (PMID: 23123060) Sci Adv. 2025 Sep 26;11(39):eadv6939. (PMID: 41004596) Nat Commun. 2023 Feb 3;14(1):588. (PMID: 36737440) Int Immunopharmacol. 2024 Aug 20;137:112484. (PMID: 38885605) Sci Immunol. 2023 Nov 3;8(89):eadi8217. (PMID: 37922339) PLoS Biol. 2007 Feb;5(2):e38. (PMID: 17298177) Cell Mol Immunol. 2016 Jul;13(4):415-7. (PMID: 26073467) Nat Commun. 2021 May 11;12(1):2710. (PMID: 33976194) J Immunol. 2014 Jan 1;192(1):475-83. (PMID: 24298014) Nat Genet. 2001 Jan;27(1):68-73. (PMID: 11138001) Nat Immunol. 2025 Nov;26(11):2059-2073. (PMID: 41062655) Front Immunol. 2024 Jul 18;15:1333150. (PMID: 39091493) Nat Commun. 2025 Oct 17;16(1):9223. (PMID: 41107262) Front Immunol. 2023 Feb 09;14:1117320. (PMID: 36845105) EMBO J. 2024 Apr;43(8):1445-1483. (PMID: 38499786) Proc Natl Acad Sci U S A. 2022 Feb 15;119(7):. (PMID: 35140181) Mol Cell Biol. 2017 Sep 26;37(20):. (PMID: 28784721) Nat Immunol. 2017 Feb;18(2):173-183. (PMID: 27992401) Nat Immunol. 2024 Aug;25(8):1395-1410. (PMID: 39009838) Blood. 2009 Nov 5;114(19):4138-41. (PMID: 19738030) J Immunol. 2016 Mar 1;196(5):2119-31. (PMID: 26826239) Nat Commun. 2025 May 7;16(1):4228. (PMID: 40335494) Sci Immunol. 2025 Jun 6;10(108):eadr7057. (PMID: 40478934) Immunity. 2019 Feb 19;50(2):493-504.e7. (PMID: 30737144) Nat Immunol. 2025 Mar;26(3):444-458. (PMID: 39905200) Nat Genet. 2001 Jan;27(1):18-20. (PMID: 11137992) Nat Commun. 2025 Feb 07;16(1):1431. (PMID: 39920158) Cell. 2014 Aug 14;158(4):734-748. (PMID: 25126782) Mol Metab. 2025 Apr;94:102111. (PMID: 39929287) Biotechnol Adv. 2026 Sep;90:108921. (PMID: 42142549) Front Immunol. 2026 Mar 27;17:1684023. (PMID: 41972131) J Mol Cell Biol. 2024 Nov 25;16(6):. (PMID: 37935468) Nat Immunol. 2025 Nov;26(11):2074-2085. (PMID: 41094201) Front Immunol. 2024 Mar 28;15:1331846. (PMID: 38605970) Immunity. 2021 Dec 14;54(12):2812-2824.e4. (PMID: 34861182) Nat Methods. 2016 Mar;13(3):229-232. (PMID: 26752769) Clin Immunol. 2018 Jun;191:116-125. (PMID: 29223407) Epigenetics Chromatin. 2017 May 8;10:24. (PMID: 28503202) Cancer Cell. 2025 Jan 13;43(1):49-68.e9. (PMID: 39642889) J Hematol Oncol. 2022 Aug 10;15(1):104. (PMID: 35948909) Circulation. 2022 Jun 7;145(23):1720-1737. (PMID: 35502657) J Immunol. 2014 Sep 1;193(5):2196-206. (PMID: 25063866) Hum Immunol. 2026 Jul;87(7):111747. (PMID: 42102540) Sci Immunol. 2023 Nov 24;8(89):eadj5789. (PMID: 37874251) Cancer Cell. 2011 Jan 18;19(1):17-30. (PMID: 21251613) Immunity. 2013 Nov 14;39(5):949-62. (PMID: 24238343) Nat Commun. 2023 Nov 6;14(1):6943. (PMID: 37932264) Ann Pediatr Endocrinol Metab. 2024 Dec;29(6):356-364. (PMID: 39778404) Oncoimmunology. 2022 Nov 4;11(1):2141007. (PMID: 36352891) Sci Immunol. 2022 Jan 14;7(67):eabj9836. (PMID: 35030035) J Immunol. 2013 Apr 1;190(7):3180-8. (PMID: 23420886) Int Immunol. 2019 Apr 26;31(5):335-347. (PMID: 30726915) Front Pharmacol. 2014 Oct 28;5:235. (PMID: 25389405) Adv Sci (Weinh). 2026 Feb;13(8):e18884. (PMID: 41454696) Sci Transl Med. 2023 Dec 20;15(727):eadg6822. (PMID: 38117899) Cancer Cell. 2021 Dec 13;39(12):1594-1609.e12. (PMID: 34767762) J Immunother Cancer. 2026 Feb 24;14(2):. (PMID: 41735000) Science. 2022 Feb 11;375(6581):681-686. (PMID: 35143307) Mol Cancer Ther. 2026 May 4;25(5):685-700. (PMID: 41423415) Nat Rev Genet. 2023 Aug;24(8):494-515. (PMID: 36864178) J Exp Med. 2020 Sep 7;217(9):. (PMID: 32515782) J Thorac Oncol. 2025 Aug;20(8):1050-1074. (PMID: 40056978) J Immunol. 2018 Mar 1;200(5):1639-1650. (PMID: 29427415) Br J Cancer. 2024 Jun;130(12):2016-2026. (PMID: 38704478) Clin Cancer Res. 2018 Mar 1;24(5):1138-1151. (PMID: 29301830) Am J Transplant. 2025 Jan;25(1):38-47. (PMID: 39299674) Nat Commun. 2024 Mar 27;15(1):2542. (PMID: 38538608) Front Immunol. 2019 Oct 11;10:2382. (PMID: 31681278) Sci Transl Med. 2024 Aug 28;16(762):eadp1720. (PMID: 39196959) Cell. 2017 Jun 1;169(6):1130-1141.e11. (PMID: 28552348) Sci Transl Med. 2024 Oct 16;16(769):eadj9331. (PMID: 39413160) Int J Mol Sci. 2026 Jun 26;27(13):. (PMID: 42450051) Nature. 2023 Apr;616(7955):113-122. (PMID: 36922587) J Immunol. 2011 Apr 1;186(7):3918-26. (PMID: 21368230) Mol Cancer Ther. 2025 Jul 2;24(7):963-975. (PMID: 40293942) Cancer Immunol Immunother. 2016 May;65(5):587-99. (PMID: 27000869) J Transl Med. 2024 Mar 4;22(1):239. (PMID: 38439077) Crit Rev Immunol. 2021;41(1):13-21. (PMID: 33822522) Mol Cell. 2017 Jan 19;65(2):323-335. (PMID: 28107650) Cells. 2026 Jan 25;15(3):. (PMID: 41677595) J Immunol. 2006 Nov 15;177(10):6940-51. (PMID: 17082609) Nat Immunol. 2023 Oct;24(10):1748-1761. (PMID: 37563308) Eur J Immunol. 2023 Sep;53(9):e2250002. (PMID: 36891988) J Immunother Cancer. 2021 Feb;9(2):. (PMID: 33589525) Cell Rep. 2018 Jun 12;23(11):3262-3274. (PMID: 29898397) PLoS One. 2016 Apr 14;11(4):e0153682. (PMID: 27077371) Mol Cells. 2016 Dec;39(12):888-897. (PMID: 27989104) Mol Cell Biol. 2014 Nov;34(21):3993-4007. (PMID: 25154413) Nature. 2019 Jan;565(7740):495-499. (PMID: 30626970) Cell Rep Methods. 2025 Dec 15;5(12):101222. (PMID: 41218606) Front Immunol. 2020 Feb 03;10:3136. (PMID: 32117202) |
| Contributed Indexing: | Keywords: CAR-Treg engineering; TET dioxygenases; TSDR demethylation; epigenetic plasticity; ex-Treg conversion; regulatory T cells (Tregs); super-enhancers |
| Substance Nomenclature: | 0 (Forkhead Transcription Factors) 0 (FOXP3 protein, human) |
| Entry Date(s): | Date Created: 20261007 Date Completed: 20261007 Latest Revision: 20261008 |
| Update Code: | 20261008 |
| PubMed Central ID: | PMC13640018 |
| DOI: | 10.3389/fimmu.2026.1952451 |
| PMID: | 42840575 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1952451 |